Antoine joined Apollo Health Ventures as a Partner in 2025.
Previously, he was a Principal at Forbion, where he sourced, led, and managed investments across biotech and therapeutics. He served as Board Director at Calluna Pharma and Mestag Therapeutics, and as Board Observer at Rectify Pharma, Azafaros, Armgo Pharma, Inversago Pharma (acquired by Novo Nordisk), and Dyne Therapeutics (NASDAQ: DYN). He also led due diligence for Versanis Bio, acquired by Eli Lilly.
Antoine holds a Ph.D. in Molecular Medicine from Laval University, where he contributed to the discovery of the RANK/RANKL/OPG molecular pathway in skeletal muscle, co-authoring over a dozen publications in muscle physiology and neuromuscular disease.
He began his career in life sciences equity research and venture capital, supporting due diligence efforts at BDC’s Healthcare Venture Fund in Canada.
Antoine joined Apollo Health Ventures as a Partner in 2025.
Previously, he was a Principal at Forbion, where he sourced, led, and managed investments across biotech and therapeutics. He served as Board Director at Calluna Pharma and Mestag Therapeutics, and as Board Observer at Rectify Pharma, Azafaros, Armgo Pharma, Inversago Pharma (acquired by Novo Nordisk), and Dyne Therapeutics (NASDAQ: DYN). He also led due diligence for Versanis Bio, acquired by Eli Lilly.
Antoine holds a Ph.D. in Molecular Medicine from Laval University, where he contributed to the discovery of the RANK/RANKL/OPG molecular pathway in skeletal muscle, co-authoring over a dozen publications in muscle physiology and neuromuscular disease.
He began his career in life sciences equity research and venture capital, supporting due diligence efforts at BDC’s Healthcare Venture Fund in Canada.
